L-arginine

Generic Name: L-arginine

Brand Names: Clinimix 2.75/5

Drug Type: Small Molecule

CAS Number: 74-79-3

Clinical Trials

Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Metformin
Drug: L-Arginine

First Posted Date: 2015-08-05

Last Posted Date: 2015-08-07

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 5

Registration Number: NCT02516085

L-arginine and Brown Adipose Tissue

Phase 3

Conditions: Adipose Tissue, Brown
Glucose Intolerance
Nitric Oxide

Interventions: Drug: L-arginine
Drug: Placebo

First Posted Date: 2014-11-14

Last Posted Date: 2014-11-14

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 26

Registration Number: NCT02291458

Locations: 🇳🇱
Maastricht University Medical Center +, Maastricht, Limburg, Netherlands

Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans

Phase 4

Completed

Conditions: Skeletal Muscle Ischemia
Severe Lower Limb Ischemia
Mitochondrial Dysfunction

Interventions: Drug: Nacl
Drug: L-arginine (L-arginine Veyron)

First Posted Date: 2014-04-17

Last Posted Date: 2014-04-17

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 60

Registration Number: NCT02117206

Locations: 🇫🇷
SERVICE DE PHYSIOLOGIE ET D'EXPLORATIONS FONCTIONNELLES- Nouvel Hôpital Civil, HUS, Strasbourg, France

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

Phase 2

Completed

Conditions: Asthma
Inflammation

Interventions: Drug: L-Arginine
Drug: Placebo

First Posted Date: 2013-04-26

Last Posted Date: 2020-04-21

Lead Sponsor: Nicholas Kenyon

Target Recruit Count: 54

Registration Number: NCT01841281

Locations: 🇺🇸
UC Davis CTSC Clinical Research Center, Sacramento, California, United States

HaemoDYNAMICs in Primary and Secondary Hypertension

Recruiting

Conditions: Primary Hypertension
Secondary Hypertension
Renal Insufficiency
Aortic Stenosis

Interventions: Drug: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)
Dietary Supplement: Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)
Drug: Salbutamol 400 µg (single dose, no longer given since January 2017)
Drug: L-arginine (10 min infusion, no longer given since January 2017)
Drug: Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)
Dietary Supplement: Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)

First Posted Date: 2012-12-05

Last Posted Date: 2021-08-19

Lead Sponsor: Tampere University

Target Recruit Count: 2000

Registration Number: NCT01742702

Locations: 🇫🇮
Tampere University Hospital, Tampere, Southern Finland, Finland
🇫🇮
Tampere University, Tampere, Southern Finland, Finland

L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

Phase 2

Completed

Conditions: MELAS Syndrome

Interventions: Drug: L-Arginine

First Posted Date: 2012-05-22

Last Posted Date: 2013-12-17

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 7

Registration Number: NCT01603446

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Prospective L-arginine Study

Phase 1

Terminated

Conditions: Heart Transplant

Interventions: Drug: L-arginine

First Posted Date: 2011-12-05

Last Posted Date: 2017-01-10

Lead Sponsor: University of Michigan

Target Recruit Count: 3

Registration Number: NCT01485757

Locations: 🇺🇸
University of Michigan Pediatric Heart Transplant Clinic, Ann Arbor, Michigan, United States

Endothelial Facilitation in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Simvastatin
Drug: L-Arginine
Drug: Tetrahydrobiopterin

First Posted Date: 2011-09-23

Last Posted Date: 2019-07-30

Lead Sponsor: University of Massachusetts, Worcester

Target Recruit Count: 11

Registration Number: NCT01439555

Locations: 🇺🇸
UMass Medical School/ UMass Memorial Medical Center, Worcester, Massachusetts, United States

Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids

Phase 1

Completed

Conditions: Dystrophinopathy
Duchenne Muscular Dystrophy
Becker's Muscular Dystrophy

Interventions: Drug: L-arginine

First Posted Date: 2011-07-07

Last Posted Date: 2012-07-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 7

Registration Number: NCT01388764

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of L-arginine and Glutamine on Preterm

Phase 2

Completed

Conditions: Sepsis
NEC

Interventions: Drug: Glutamine
Drug: l-arginine

First Posted Date: 2010-12-20

Last Posted Date: 2014-04-15

Lead Sponsor: Ain Shams University

Target Recruit Count: 75

Registration Number: NCT01263041

Locations: 🇪🇬
NICU of Children hospital and Nicu of obstetric and gynecology hospital, ain shams university, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy